Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TYK MedicinesHKSE:02410 -4.08%7 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 734 Biotechnology companies, TYK Medicines ranks worse than 136239.65% on this metric.
The historical rank and industry rank for TYK Medicines's Gross Margin % or its related term are showing as below:
During the past 4 years, the highestGross Margin % of TYK Medicines was 45.30%. The lowest was 13.16%. And the median was 29.23%.
HKSE:02410's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.905 * Ranked among companies with meaningful Gross Margin % only.
TYK Medicines had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for TYK Medicines was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
TYK Medicines had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
TYK Medicines Gross Margin % Related Terms
TYK Medicines Gross Margin % Historical Data
* Premium members only.
The historical data trend for TYK Medicines's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02410 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, TYK Medicines's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TYK Medicines Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TYK Medicines's Gross Margin % distribution charts can be found below:
* The bar in red indicates where TYK Medicines's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
TYK Medicines (HKSE:02410) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on TYK Medicines and its competitors. Over the past decade, TYK Medicines' Gross Margin % has ranged from 13.16 to 45.30. According to the industry distribution chart, TYK Medicines ranks #999999 out of 734 companies in the Biotechnology industry.
Is TYK Medicines' Gross Margin % too high?
TYK Medicines' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 13.16 to a high of 45.30. Based on the distribution chart, TYK Medicines ranks #999999 out of 734 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TYK Medicines ranks #999999 out of 734 companies for Gross Margin %. This places TYK Medicines in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, TYK Medicines' own Gross Margin % has ranged from 13.16 to 45.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on TYK Medicines and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TYK Medicines's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score
Get the complete analysis for HKSE:02410
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02410 has been successfully added to your 
